vs
Lipocine Inc.（LPCN）与ScanTech AI Systems Inc.（STAI）财务数据对比。点击上方公司名可切换其他公司
Lipocine Inc.的季度营收约是ScanTech AI Systems Inc.的1.8倍（$1.1M vs $631.0K）
Lipocine Inc是一家处于临床阶段的生物制药企业，专注于激素相关疗法的研发，核心管线覆盖男性健康、女性健康及肝病领域的未满足医疗需求，主要运营与市场布局集中在美国，致力于开发口服制剂以提升患者治疗体验。
LPCN vs STAI — 直观对比
营收规模更大
LPCN
是对方的1.8倍
$631.0K
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1M | $631.0K |
| 净利润 | — | $-9.7M |
| 毛利率 | — | 27.6% |
| 营业利润率 | — | -773.2% |
| 净利率 | — | -1532.9% |
| 营收同比 | -67.2% | — |
| 净利润同比 | -233.0% | — |
| 每股收益（稀释后） | — | $-0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LPCNSTAI
| Q4 25 | $1.1M | — | ||
| Q3 25 | — | $631.0K | ||
| Q2 25 | — | $884.0K | ||
| Q1 25 | — | $346.1K | ||
| Q3 24 | $0 | — | ||
| Q1 24 | $7.6M | — |
净利润LPCNSTAI
| Q4 25 | — | — | ||
| Q3 25 | — | $-9.7M | ||
| Q2 25 | — | $-6.9M | ||
| Q1 25 | — | $-17.9M | ||
| Q3 24 | $-2.2M | — | ||
| Q1 24 | $3.5M | — |
毛利率LPCNSTAI
| Q4 25 | — | — | ||
| Q3 25 | — | 27.6% | ||
| Q2 25 | — | 14.3% | ||
| Q1 25 | — | 29.4% | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — |
营业利润率LPCNSTAI
| Q4 25 | — | — | ||
| Q3 25 | — | -773.2% | ||
| Q2 25 | — | -440.1% | ||
| Q1 25 | — | -4503.9% | ||
| Q3 24 | — | — | ||
| Q1 24 | 42.3% | — |
净利率LPCNSTAI
| Q4 25 | — | — | ||
| Q3 25 | — | -1532.9% | ||
| Q2 25 | — | -785.1% | ||
| Q1 25 | — | -5174.2% | ||
| Q3 24 | — | — | ||
| Q1 24 | 46.1% | — |
每股收益（稀释后）LPCNSTAI
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.16 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.77 | ||
| Q3 24 | $-0.44 | — | ||
| Q1 24 | $0.66 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.2M | — |
| 总债务越低越好 | — | $17.7M |
| 股东权益账面价值 | $14.5M | — |
| 总资产 | $17.0M | $5.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LPCNSTAI
| Q4 25 | $5.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | $3.7M | — | ||
| Q1 24 | $3.1M | — |
总债务LPCNSTAI
| Q4 25 | — | — | ||
| Q3 25 | — | $17.7M | ||
| Q2 25 | — | $17.7M | ||
| Q1 25 | — | $17.7M | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — |
股东权益LPCNSTAI
| Q4 25 | $14.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | $19.1M | — | ||
| Q1 24 | $24.0M | — |
总资产LPCNSTAI
| Q4 25 | $17.0M | — | ||
| Q3 25 | — | $5.1M | ||
| Q2 25 | — | $4.6M | ||
| Q1 25 | — | $5.1M | ||
| Q3 24 | $20.7M | — | ||
| Q1 24 | $25.4M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-9.8M | $-758.5K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流LPCNSTAI
| Q4 25 | $-9.8M | — | ||
| Q3 25 | — | $-758.5K | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-2.2M | ||
| Q3 24 | $-2.8M | — | ||
| Q1 24 | $2.4M | — |
自由现金流LPCNSTAI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-2.2M | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率LPCNSTAI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -166.0% | ||
| Q1 25 | — | -623.8% | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度LPCNSTAI
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 2.0% | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — |
现金转化率LPCNSTAI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | 0.69× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
